Xu Wang1, Jiuwei Cui1, Jingkai Gu2,3, Hua He1, Biao Li1, Wei Li1. 1. Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China. 2. Clinical Pharmacology Center, Research Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, Jilin, China. 3. Research Center for Drug Metabolism, Jilin University, Changchun, Jilin, China.
Abstract
BACKGROUND: The association between vitamin D levels and lung cancer risk varies among distinct demographic populations; however, whether vitamin D levels are related to the risk of lung cancer in Chinese population is unknown. OBJECTIVE: We aimed to elucidate the association of plasma 25-hydroxyvitamin D [25(OH)D] level with the risk of non-small cell lung cancer (NSCLC) in a Chinese population. METHODS: A total of 100 NSCLC patients and, 100 age-, gender-, blood-collection-season- and resident area-matched, cancer-free controls were recruited. Plasma 25(OH)D2 and 25(OH)D3 levels were measured by LC/MS/MS mass spectrometry and HPLC. A logistic regression model was applied to estimate the association between 25(OH)D concentrations and NSCLC risk. RESULTS: Multivariable analysis showed that smoking history, and 25(OH)D deficiency (< 20 ng/mL) were related to a higher risk of NSCLC (P = 0.03). In addition, late stage (stage IIIB-IV) NSCLC was associated with lower 25(OH)D levels, as indicated by univariate analysis. Similarly, multivariate analysis showed that late stage (IIIB-IV) NSCLC was related to 25(OH)D deficiency. CONCLUSIONS: Plasma 25(OH)D deficiency is significantly associated with a higher risk of NSCLC, specifically late stage NSCLC.
BACKGROUND: The association between vitamin D levels and lung cancer risk varies among distinct demographic populations; however, whether vitamin D levels are related to the risk of lung cancer in Chinese population is unknown. OBJECTIVE: We aimed to elucidate the association of plasma 25-hydroxyvitamin D [25(OH)D] level with the risk of non-small cell lung cancer (NSCLC) in a Chinese population. METHODS: A total of 100 NSCLCpatients and, 100 age-, gender-, blood-collection-season- and resident area-matched, cancer-free controls were recruited. Plasma 25(OH)D2 and 25(OH)D3 levels were measured by LC/MS/MS mass spectrometry and HPLC. A logistic regression model was applied to estimate the association between 25(OH)D concentrations and NSCLC risk. RESULTS: Multivariable analysis showed that smoking history, and 25(OH)D deficiency (< 20 ng/mL) were related to a higher risk of NSCLC (P = 0.03). In addition, late stage (stage IIIB-IV) NSCLC was associated with lower 25(OH)D levels, as indicated by univariate analysis. Similarly, multivariate analysis showed that late stage (IIIB-IV) NSCLC was related to 25(OH)D deficiency. CONCLUSIONS: Plasma 25(OH)D deficiency is significantly associated with a higher risk of NSCLC, specifically late stage NSCLC.
Entities:
Keywords:
25-hydroxyvitamin D; lung cancer; non-small cell lung cancer
Authors: Majda Haznadar; Kristopher W Krausz; Ezra Margono; Christopher M Diehl; Elise D Bowman; Soumen Kanti Manna; Ana I Robles; Bríd M Ryan; Frank J Gonzalez; Curtis C Harris Journal: Cancer Med Date: 2018-05-03 Impact factor: 4.452